Introduction {#sec0005}
============

The coronavirus 2019 (COVID-19) pandemic has taken the world by surprise as it viciously spread through the continents with rapidly increasing mortality rates. Current management of COVID-19 is based on the premise that respiratory failure is the leading cause of fatalities ([@bib0140]). Nevertheless, mounting evidence points to drastic systemic events taking place that contribute to accelerated COVID-19 pathogenesis. The "cytokine storm" is a notion that is reportedly hailed as the hallmark of the COVID-19 hyper-inflammatory state ([@bib0075]). Consecutive studies linked COVID-19 related hyper-inflammation to systemic events including hypercoagulability, oxidative stress and altered iron metabolism ([@bib0075], [@bib0100]). These events were linked to accelerated pathogenesis in gravely ill COVID-19 patients as highlighted in a recent perspective ([@bib0085]). Several components of the heightened inflammatory state have been proposed as therapeutic targets, particularly IL-6 blockers as drugs of more relevance in COVID-19 management than steroids, however concerns of prolonging viral clearance were stated ([@bib0085]).

Hyper-ferritinemia has been described as a cardinal feature that predicted with high significance the increased mortality risk ([@bib0075], [@bib0100]). These studies demonstrated serum ferritin levels in COVID-19 non-survivors that exceeded the levels in the survivors by two-fold. In spite of the strong association with mortality, it is not yet clear if hyper-ferritinemia in COVID-19 patients is merely a systemic marker of disease progression, or a key modulator in disease pathogenesis.

Recently we showed that hepcidin, the key iron regulatory molecule, plays a major role during inflammatory processes ([@bib0005]). However, the role and management of a dysregulated iron state in COVID-19 pathogenesis has not yet been addressed.

Is iron a key strategic player in COVID-19 pathogenesis? {#sec0010}
========================================================

Increasing evidence shows that inflammation, oxidative stress and altered iron homeostasis are inevitably linked at a systemic level ([@bib0055]). This perspective elaborates on the potential aspect of altered iron homeostasis, marked by hyper-ferritinemia, and its potential role in COVID-19 pathogenesis and management strategies.

Iron is an essential trace element that plays a role in systemic oxygen transfer, and acts as an electron donor or acceptor in many biological functions. Ferritin is the primary site of iron storage in the cell mainly in its ferric state (Fe3+). Ferritin can carry up to 4500 iron molecules in its core ([@bib0050]). Generally, systemic inflammations are associated with increased serum ferritin levels. During a heightened inflammatory state, cytokines, particularly IL-6, stimulate ferritin and hepcidin synthesis ([@bib0070], [@bib0015]).

Hepcidin, the key iron regulatory hormone, sequesters iron in the enterocytes and macrophages, leading to increased intracellular ferritin, and preventing iron efflux from enterocytes and macrophages ([@bib0015]) ([Figure 1](#fig0005){ref-type="fig"} ). Thereby, we speculate that increased serum ferritin levels as a result of COVID-19 related hyper-inflammation signify a vicious cycle of events where increased ferritin levels may lead to further tissue damage ([@bib0050]).Figure 1COVID-19 infection and Iron dysregulation.COVID-19 infection results in an inflammatory state involving a cytokine storm in COVID-19 patients. IL-6 stimulates ferritin and the synthesis of hepcidin. Hepcidin sequesters iron in the enterocytes and macrophages, leading to increased intracellular ferritin, and preventing iron efflux from enterocytes and macrophages. Excess intracellular iron interacts with molecular oxygen, generating reactive oxygen species (ROS) through Haber-Weiss and Fenton reactions and reactive nitrogen species (RNS) and reactive sulfur species (RSS). The intracellular iron excess leads to ferroptosis, a process of programmed cell death. Iron overload may also affect extra and intracellular mitochondria function and microbiota diversity (lungs and gut) and blood coagulation.Figure 1

Excess intracellular iron interacts with molecular oxygen, generating reactive oxygen species (ROS) ([@bib0050]). This may largely contribute to oxidative damage of cellular components of different organs (lungs, liver, kidney, heart). Mounting evidence links increased ferritin levels to various inflammatory pathologies including cardiovascular events ([@bib0060]). Moreover, the complex interplay between iron metabolism and reactive nitrogen species (RNS) and reactive sulfur species (RSS) in addition to ROS suggests a clear interaction between iron metabolism and the newly defined reactive species interactome ([@bib0010]) ([Figure 1](#fig0005){ref-type="fig"}).

Interestingly, recent studies implicated that ferroptosis, which is the process of programmed cell death mediated by iron-dependent peroxidation mechanisms ([@bib0125]) in inflammatory pathologies, involves multiple organs including liver, kidney, heart and lung ([@bib0120]). Ferroptosis was found to be linked to neurological disturbances including cognitive impairment ([@bib0120]), agueusia and anosmia (taste and smell loss) ([@bib0090], [@bib0020]) that are regular manifestations of COVID-19 disease ([@bib0130]). Iron chelators and ferroptosis inhibitors had protective effects by inhibiting intracellular iron induced lipid peroxidation ([@bib0055]). The impact of iron overload on extra and intracellular mitochondria dysfunction ([@bib0110]), on microbiota dysbiosis (lungs and gut) ([@bib0145]) and on other pathogens may be strongly implicated as shown in [Figure 1](#fig0005){ref-type="fig"}.

Furthermore, serum coagulability is a major concern in COVID-19 pathogenesis, and rapidly recognized as a key risk factor in susceptible patients ([@bib0035], [@bib0065], [@bib0095], [@bib0135]). In the context of the cellular iron overload, it has long been documented that coagulopathy is a hallmark of iron toxicity. Oxidized iron accelerates serum coagulation by interacting with proteins of coagulation cascade ([@bib0045]).

Coagulation and cardiac biomarkers have been described to be elevated in COVID-19 patients, reflecting an inflammatory status characterized by coagulation activation and vascular endothelial dysfunction, found to be predictors of mortality ([@bib0035], [@bib0065]). A recent report demonstrated acute formation of large vessel strokes in young adults infected with COVID-19 ([@bib0095]). The inflammation in the blood vessel walls and platelets mitochondria alteration may be driving thrombosis formation ([@bib0035], [@bib0065], [@bib0095], [@bib0135]).

Conclusion {#sec0015}
==========

Hyper-ferritinemia observed in COVID-19 patients may be induced in response to inflammation. However, its role in COVID-19 disease progression has not been fully established. It has been reported that hyper-inflammation in association with altered iron homeostasis may play a key role in pathogenesis of disease including viral infections ([@bib0025], [@bib0115]) ([Figure 1](#fig0005){ref-type="fig"}). It may be postulated that hyper-ferritinemia is associated with a state of iron toxicity which may result from increased ferritin leakage from damaged tissue releasing free iron in the process. There is no established consensus to exclude this possibility. Therefore, it is crucial to investigate coexisting iron parameters in COVID-19 patients including transferrin saturation, plasma iron levels, non-transferrin bound iron (NTBI) as well as hepcidin. The association of hyper-ferritinemia with increased transferrin saturation may reflect a state of iron overload. In this case, we suggest that targeting the intracellular iron overload may be a strategy of vital importance needed to be taken into consideration in future controlled clinical trials.

We suggest, in addition to treatment of the inflammatory state ([@bib0085]), to envisage the application of approved iron chelators, ferroptosis inhibitors, hepcidin modulators and erythropoietin ([@bib0080], [@bib0105], [@bib0030], [@bib0005], [@bib0040]). This promising therapeutic approach can be associated with drugs that specifically target extra and intracellular mitochondria dysfunction or even the reactive species interactome production and ferroptosis ([@bib0010], [@bib0055]) ([Figure 1](#fig0005){ref-type="fig"}).
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